CLARITY IN
CANCER CARE

Latest news

Successful installation and proton beam testings of Qualγscan®
Skandion Clinic, Sweden in October 2023.
Measured dose in 3D
by Qualγscan®
view-head
Successful installation and carbon ion beam testings of Qualγscan®
Yonsei Cancer Center, South Korea in September 2024
Link to the News
End-to-End Quality Assurance Device

Meet our first product: Qualyscan. Our all-in-one solution for mastering quality control in Proton Therapy.

More
About us

Next generation imaging technology taking nuclear and precision medicine to the next level

Terapet SA, a Geneva-based CERN MedTech spin-off, has developed an innovative platform technology for imaging in nuclear medicine, taking proton therapy and nuclear imaging to the next level.

More
Mission and Vision of our company

Next Generation Imaging Technology

Terapet’s mission is to use our innovative platform technology to develop integrated imaging solutions, taking proton therapy, nuclear imaging and precision medicine to the next level.

Terapet envisions that its Qualyscan™ and Nuclyscan™ will enable QUALITY and NEW CLINICAL nuclear imaging in every patient’s diagnosis and treatment, making them the first choice for radiotherapy and precision medicine in the near future.

We are collaborating with
We are supported by
Our Awards